In recent years, new regulatory requirements around pharmacovigilance have been introduced in all regions. The following three trends represent a major departure from the traditional and more reactive model of pharmacovigilance:
1. A shift from a passive to active surveillance
2. A strong emphasis on risk-benefit balance
3. Globalization of pharmacovigilance
Above trends bring about several challenges and opportunities that a biopharmaceutical company need to address when building an effective pharmacovigilance system. Explore more in this white paper.